Page last updated: 2024-12-06
granisetron hydrochloride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918003 |
| CHEMBL ID | 1900758 |
| CHEBI ID | 5538 |
| SCHEMBL ID | 34177 |
| SCHEMBL ID | 34179 |
| MeSH ID | M0329234 |
Synonyms (58)
| Synonym |
|---|
| syb l-0701 |
| granisol |
| alm-101 |
| bema-granisetron |
| granisetron-mdts |
| brl 43694a |
| endo-1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-1h-indazole-3-carboxamide hydrochloride |
| kytril injection |
| granisetron hydrochloride [usan] |
| 1-methyl-n-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1h-indazole-3-carboxamide monohydrochloride |
| 1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, monohydrochloride, endo- |
| kytril (tn) |
| granisetron hydrochloride (jan/usp) |
| D00677 |
| smr000469138 |
| MLS001401373 |
| 1-methyl-n-((1r,3r,5s)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1h-indazole-3-carboxamide hydrochlorid |
| A801552 |
| 1-methyl-n-[(1s,5r)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide hydrochloride |
| granisetron hydrochloride [usan:usp] |
| unii-318f6l70j8 |
| 318f6l70j8 , |
| nsc 759839 |
| granisetron hydrochloride preservative free |
| cas-107007-99-8 |
| dtxsid7049057 , |
| tox21_113607 |
| dtxcid2028983 |
| CCG-101117 |
| BCP9000731 |
| granisetron hydrochloride [who-dd] |
| granisetron hydrochloride [orange book] |
| granisetron hydrochloride [usp monograph] |
| granisetron hydrochloride [mart.] |
| granisetron hydrochloride [usp-rs] |
| granisetron hydrochloride [vandf] |
| granisetron hydrochloride [usp impurity] |
| granisetron hydrochloride [ep monograph] |
| granisetron hydrochloride [ep impurity] |
| granisetron hydrochloride [jan] |
| granisetron hydrochloride [mi] |
| AKOS025311206 |
| NC00367 |
| G0401 |
| SCHEMBL34177 |
| SCHEMBL34179 |
| CHEMBL1900758 |
| mfcd01747034 |
| granisetron hydrochloride, united states pharmacopeia (usp) reference standard |
| granisetron hydrochloride, >=98% (hplc), solid |
| granisetron hydrochloride, pharmaceutical secondary standard; certified reference material |
| granisetron hydrochloride, european pharmacopoeia (ep) reference standard |
| CHEBI:5538 |
| Q27256024 |
| T71574 |
| GLXC-03045 |
| EN300-24410959 |
| 1-methyl-n-[(1r,3r,5s)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-1h-indazole-3-carboxamide hydrochloride |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| indazoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 37.6858 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 33.4915 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 5.0119 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (77)
Molecular Functions (26)
Ceullar Components (22)
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||